GlassScriptPhysician profile
Ranjith Wijeratne
NPI 1376745356
$4,155.50
in general payments reported to CMS, 2019-2025
16 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2021: $86.70 · 2022: $190 · 2023: $1,394 · 2024: $574 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,360 · Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,360.47 |
| Food and Beverage | $1,335.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,328.79 | 2025 | Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655, Olympus |
| Ovesco Endoscopy USA, INC. | $1,148.11 | 2023 | |
| Olympus America INC. | $692.87 | 2022-2025 | Visiglide, Disposable Biopsy Forceps, Hanarostent Biliary (Nnn) |
| Abbvie INC. | $274.98 | 2019-2025 | |
| Conmed Corporation | $151.36 | 2024-2025 | Conmed Biliary, Conmed Hemostasis |
| Axonics, INC. | $113.77 | 2022 | |
| Erbe USA INC | $92.60 | 2023 | Erbe Vio3 Apc3 |
| Micro-Tech Endoscopy USA, INC. | $89.86 | 2024-2025 | Eyemax, Cold Snares |
| Boston Scientific Corporation | $65.46 | 2025 | Overstitch Endoscopic Suturing System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.94 | 2021-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $51.34 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $22.31 | 2023 | Simponi, Stelara, Remicade |
| Lilly USA, LLC | $18.29 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $17.15 | 2024 | Resmetirom |
| Regeneron Healthcare Solutions, INC. | $17.11 | 2024 | Dupixent |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.56 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjith Wijeratne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.